摘要
类风湿关节炎相关间质性肺疾病(RA-ILD)目前无公认的治疗方案,需要权衡治疗的获益和风险,因此,准确的评估和判断患者预后有助于指导临床治疗、优化医疗资源配置、减轻社会经济负担。本文将对目前发现的影响RA-ILD患者临床预后的相关因素以及药物治疗新进展进行总结。
For now,there is no approved treatments for rheumatoid arthritis-associated interstitial lung disease(RA-ILD),and the benefits and risks of treatment need to be well balanced before therapy.Therefore,accurate assessment and prognosis judgement are helpful to guide clinical treatment,optimize medical resource allocation,and reduce social and economic burden.In this paper,the related factors affecting the clinical prognosis of patients with RA-ILD and new advances in drug therapy were summarized.
作者
陈梁欣
彭翔
CHEN Liang-xin;PENG Xiang(Graduate School of Guangzhou Medical University,Guangzhou 510182,China;不详)
出处
《中国处方药》
2022年第1期179-181,共3页
Journal of China Prescription Drug
关键词
类风湿关节炎相关间质性肺疾病
预后因素
综述
Rheumatoid arthritis-associated interstitial lung disease
Prognostic factor
Review
